Delving into the Latest Updates on LX-132 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

Target-

Action-

Mechanism-

Therapeutic Areas

Neoplasms

Active Indication

Advanced Malignant Solid Neoplasm

Inactive Indication-

Originator Organization

Guangzhou Lixin Biotechnology Co., Ltd.

Active Organization

Guangzhou Lixin Biotechnology Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

Ⅰa期：主要目的：评价LX-132胶囊在标准治疗失败的复发或者转移性实体瘤患者中的安全性和耐受性，并确定最大耐受剂量（MTD）和/或推荐的后续临床试验给药方案和剂量。 Ⅰb期：主要目的：评估LX-132胶囊在标准治疗失败的复发或者转移性实体瘤患者中的抗肿瘤疗效。

[Translation]

Phase Ia: Main purpose: To evaluate the safety and tolerability of LX-132 capsules in patients with recurrent or metastatic solid tumors who have failed standard treatment, and to determine the maximum tolerated dose (MTD) and/or recommended dosing regimen and dose for subsequent clinical trials. Phase Ib: Main purpose: To evaluate the anti-tumor efficacy of LX-132 capsules in patients with recurrent or metastatic solid tumors who have failed standard treatment.

Start Date-

Sponsor / Collaborator

Guangzhou Lixin Biotechnology Co., Ltd.

100 Clinical Results associated with LX-132

Login to view more data

100 Translational Medicine associated with LX-132

Login to view more data

100 Patents (Medical) associated with LX-132

Login to view more data

100 Deals associated with LX-132

Login to view more data